132 related articles for article (PubMed ID: 29862615)
1. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.
Focà E; Cavaglià G; Rusconi S; Cascavilla A; Cenderello G; Re A; Casari S; van den Bogaart L; Zinzani PL; Caracciolo D; Di Perri G; Bonito A; Lucchini A; Cassola G; Viale P; Calcagno A
HIV Med; 2018 Jun; ():. PubMed ID: 29862615
[TBL] [Abstract][Full Text] [Related]
2. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis.
Sombogaard F; Franssen EJF; Terpstra WE; Kerver ED; van den Berk GEL; Crul M
Int J Clin Pharm; 2018 Oct; 40(5):1402-1408. PubMed ID: 29948741
[TBL] [Abstract][Full Text] [Related]
3. HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy.
Castelli R; Schiavon R; Preti C; Ferraris L
Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):175-180. PubMed ID: 32294049
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
[TBL] [Abstract][Full Text] [Related]
6. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
8. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study.
Wong AY; Marcotte S; Laroche M; Sheehan NL; Kukreti V; Routy JP; Lemieux B; Seki JT; Rouleau D; Tseng A
Antivir Ther; 2013; 18(5):699-707. PubMed ID: 23640963
[TBL] [Abstract][Full Text] [Related]
10. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.
Gopal S; Patel MR; Yanik EL; Cole SR; Achenbach CJ; Napravnik S; Burkholder GA; Reid EG; Rodriguez B; Deeks SG; Mayer KH; Moore RD; Kitahata MM; Eron JJ; Richards KL
J Natl Cancer Inst; 2013 Aug; 105(16):1221-9. PubMed ID: 23892362
[TBL] [Abstract][Full Text] [Related]
11. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
12. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
[TBL] [Abstract][Full Text] [Related]
14. Convenience, efficacy, safety, and durability of INSTI-based antiretroviral therapies: evidence from the Italian MaSTER cohort.
Rich SN; Nasta P; Quiros-Roldan E; Fusco P; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G;
Eur J Med Res; 2023 Aug; 28(1):292. PubMed ID: 37596688
[TBL] [Abstract][Full Text] [Related]
15. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
[TBL] [Abstract][Full Text] [Related]
16. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.
Kowalkowski MA; Mims MA; Day RS; Du XL; Chan W; Chiao EY
Cancer Epidemiol; 2014 Aug; 38(4):386-92. PubMed ID: 24947588
[TBL] [Abstract][Full Text] [Related]
17. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011-2017.
Korten V; Gökengin D; Eren G; Yıldırmak T; Gencer S; Eraksoy H; Inan D; Kaptan F; Dokuzoğuz B; Karaoğlan I; Willke A; Gönen M; Ergönül Ö;
AIDS Res Ther; 2021 Jan; 18(1):4. PubMed ID: 33422112
[TBL] [Abstract][Full Text] [Related]
18. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
19. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
Lim KJC; Di Ciaccio P; Polizzotto MN; Milliken S; Cochrane T; Goh Z; Shaw B; Perry E; Gilbertson M; Kermode W; Cheah CY; Latimer M; Hamad N; Ku M
Br J Haematol; 2023 Jun; 201(5):865-873. PubMed ID: 36866733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
